

# Luca Costantino

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/160096/luca-costantino-publications-by-citations.pdf>

**Version:** 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

85  
papers

3,751  
citations

32  
h-index

59  
g-index

91  
ext. papers

4,056  
ext. citations

5.8  
avg, IF

5.1  
L-index

#	Paper	IF	Citations
85	Privileged Structures as Leads in Medicinal Chemistry. <i>Current Medicinal Chemistry</i> , <b>2006</b> , 13, 65-85	4.3	295
84	Soft docking and multiple receptor conformations in virtual screening. <i>Journal of Medicinal Chemistry</i> , <b>2004</b> , 47, 5076-84	8.3	199
83	Synthesis and aldose reductase inhibitory activity of 5-arylidene-2,4-thiazolidinediones. <i>Bioorganic and Medicinal Chemistry</i> , <b>2002</b> , 10, 1077-84	3.4	188
82	Targeting the central nervous system: in vivo experiments with peptide-derivatized nanoparticles loaded with Loperamide and Rhodamine-123. <i>Journal of Controlled Release</i> , <b>2007</b> , 122, 1-9	11.7	187
81	Peptide-derivatized biodegradable nanoparticles able to cross the blood-brain barrier. <i>Journal of Controlled Release</i> , <b>2005</b> , 108, 84-96	11.7	184
80	Polymeric nanoparticles for the drug delivery to the central nervous system. <i>Expert Opinion on Drug Delivery</i> , <b>2008</b> , 5, 155-74	8	161
79	Binding of beta-carbolines and related agents at serotonin (5-HT(2) and 5-HT(1A)), dopamine (D(2)) and benzodiazepine receptors. <i>Drug and Alcohol Dependence</i> , <b>2000</b> , 60, 121-32	4.9	153
78	Activity of polyphenolic crude extracts as scavengers of superoxide radicals and inhibitors of xanthine oxidase. <i>Planta Medica</i> , <b>1992</b> , 58, 342-4	3.1	137
77	Diabetes complications and their potential prevention: aldose reductase inhibition and other approaches. <i>Medicinal Research Reviews</i> , <b>1999</b> , 19, 3-23	14.4	133
76	Nanoparticles as drug delivery agents specific for CNS: in vivo biodistribution. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , <b>2009</b> , 5, 369-77	6	110
75	Sialic acid and glycopeptides conjugated PLGA nanoparticles for central nervous system targeting: In vivo pharmacological evidence and biodistribution. <i>Journal of Controlled Release</i> , <b>2010</b> , 145, 49-57	11.7	96
74	Interaction of nanoparticles with immunocompetent cells: nanosafety considerations. <i>Nanomedicine</i> , <b>2012</b> , 7, 121-31	5.6	87
73	Synthesis, activity, and molecular modeling of a new series of tricyclic pyridazinones as selective aldose reductase inhibitors. <i>Journal of Medicinal Chemistry</i> , <b>1996</b> , 39, 4396-405	8.3	85
72	1-Benzopyran-4-one antioxidants as aldose reductase inhibitors. <i>Journal of Medicinal Chemistry</i> , <b>1999</b> , 42, 1881-93	8.3	82
71	STAT 3 as a target for cancer drug discovery. <i>Current Medicinal Chemistry</i> , <b>2008</b> , 15, 834-43	4.3	81
70	Is there a clinical future for polymeric nanoparticles as brain-targeting drug delivery agents?. <i>Drug Discovery Today</i> , <b>2012</b> , 17, 367-78	8.8	76
69	Pharmacological approaches to the treatment of diabetic complications. <i>Expert Opinion on Therapeutic Patents</i> , <b>2000</b> , 10, 1245-1262	6.8	65

68	Nanoparticulate drug carriers based on hybrid poly(D,L-lactide-co-glycolide)-dendron structures. <i>Biomaterials</i> , <b>2006</b> , 27, 4635-45	15.6	64
67	PLGA nanoparticles surface decorated with the sialic acid, N-acetylneuraminic acid. <i>Biomaterials</i> , <b>2010</b> , 31, 3395-403	15.6	56
66	New aldose reductase inhibitors as potential agents for the prevention of long-term diabetic complications. <i>Expert Opinion on Therapeutic Patents</i> , <b>1997</b> , 7, 843-858	6.8	55
65	Discovery of new inhibitors of aldose reductase from molecular docking and database screening. <i>Bioorganic and Medicinal Chemistry</i> , <b>2002</b> , 10, 1437-50	3.4	52
64	Oxidative modification of aldose reductase induced by copper ion. Definition of the metal-protein interaction mechanism. <i>Journal of Biological Chemistry</i> , <b>2002</b> , 277, 42017-27	5.4	51
63	Designed multiple ligands: basic research vs clinical outcomes. <i>Current Medicinal Chemistry</i> , <b>2012</b> , 19, 3353-87	4.3	47
62	Synthesis and activity of a new series of chalcones as aldose reductase inhibitors. <i>European Journal of Medicinal Chemistry</i> , <b>1998</b> , 33, 859-866	6.8	43
61	Nose-to-brain drug delivery by nanoparticles in the treatment of neurological disorders. <i>Current Medicinal Chemistry</i> , <b>2014</b> , 21, 4247-56	4.3	42
60	Isolation and pharmacological activities of the Tecoma stans alkaloids. <i>Il Farmaco</i> , <b>2003</b> , 58, 781-5		39
59	Discovery and development of novel salicylate synthase (MbtI) furanic inhibitors as antitubercular agents. <i>European Journal of Medicinal Chemistry</i> , <b>2018</b> , 155, 754-763	6.8	38
58	Synthesis, activity and molecular modeling of a new series of chromones as low molecular weight protein tyrosine phosphatase inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , <b>2009</b> , 17, 2658-72	3.4	35
57	A rational approach to the design of flavones as xanthine oxidase inhibitors. <i>European Journal of Medicinal Chemistry</i> , <b>1996</b> , 31, 693-699	6.8	34
56	Surface engineering of Solid Lipid Nanoparticle assemblies by methyl $\beta$ -mannopyranoside for the active targeting to macrophages in anti-tuberculosis inhalation therapy. <i>International Journal of Pharmaceutics</i> , <b>2017</b> , 528, 440-451	6.5	33
55	A Model of the Interaction of Substrates and Inhibitors with Xanthine Oxidase. <i>Journal of the American Chemical Society</i> , <b>1997</b> , 119, 3007-3016	16.4	33
54	Synthesis and biological evaluation of new imidazole, pyrimidine, and purine derivatives and analogs as inhibitors of xanthine oxidase. <i>Journal of Medicinal Chemistry</i> , <b>1996</b> , 39, 2529-35	8.3	32
53	Profiling of Flavonol Derivatives for the Development of Antitrypanosomatidic Drugs. <i>Journal of Medicinal Chemistry</i> , <b>2016</b> , 59, 7598-616	8.3	30
52	Structural bases for the inhibition of aldose reductase by phenolic compounds. <i>Bioorganic and Medicinal Chemistry</i> , <b>2000</b> , 8, 1151-8	3.4	30
51	Aldose reductase does catalyse the reduction of glyceraldehyde through a stoichiometric oxidation of NADPH. <i>Experimental Eye Research</i> , <b>2000</b> , 71, 515-21	3.7	30

50	Isoxazolo-[3,4-d]-pyridazin-7-(6H)-one as a potential substrate for new aldose reductase inhibitors. <i>Journal of Medicinal Chemistry</i> , <b>1999</b> , 42, 1894-900	8.3	30
49	Iron Acquisition Pathways as Targets for Antitubercular Drugs. <i>Current Medicinal Chemistry</i> , <b>2016</b> , 23, 4009-4026	4.3	27
48	Newly synthesized surfactants for surface mannosylation of respirable SLN assemblies to target macrophages in tuberculosis therapy. <i>Drug Delivery and Translational Research</i> , <b>2019</b> , 9, 298-310	6.2	25
47	AFM phase imaging of soft-hydrated samples: a versatile tool to complete the chemical-physical study of liposomes. <i>Journal of Liposome Research</i> , <b>2009</b> , 19, 59-67	6.1	24
46	Structure-based design of an inhibitor modeled at the substrate active site of aldose reductase. <i>Bioorganic and Medicinal Chemistry Letters</i> , <b>1997</b> , 7, 1897-1902	2.9	24
45	Inhibition of lens aldose reductase by biflavones from <i>Ouratea spectabilis</i> . <i>Planta Medica</i> , <b>1995</b> , 61, 217-220	3.0	24
44	Chapter 3 - Colloidal systems for CNS drug delivery. <i>Progress in Brain Research</i> , <b>2009</b> , 180, 35-69	2.9	23
43	Magnetic and optical bistability in tetrairon(III) single molecule magnets functionalized with azobenzene groups. <i>Dalton Transactions</i> , <b>2012</b> , 41, 8368-78	4.3	22
42	In Vivo Biodistribution of Respirable Solid Lipid Nanoparticles Surface-Decorated with a Mannose-Based Surfactant: A Promising Tool for Pulmonary Tuberculosis Treatment?. <i>Nanomaterials</i> , <b>2020</b> , 10,	5.4	21
41	New Chromane-Based Derivatives as Inhibitors of Salicylate Synthase (MbtI): Preliminary Biological Evaluation and Molecular Modeling Studies. <i>Molecules</i> , <b>2018</b> , 23,	4.8	21
40	Synthesis and structure-activity relationships of 1-aralkyl-4-benzylpiperidine and 1-aralkyl-4-benzylpiperazine derivatives as potent sigma ligands. <i>Journal of Medicinal Chemistry</i> , <b>2005</b> , 48, 266-73	8.3	20
39	Nitrophenyl derivatives as aldose reductase inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , <b>2002</b> , 10, 3923-31	3.4	20
38	Aryl thiosemicarbazones for the treatment of trypanosomatidic infections. <i>European Journal of Medicinal Chemistry</i> , <b>2018</b> , 146, 423-434	6.8	19
37	Oxidative modification of aldose reductase induced by copper ion. Factors and conditions affecting the process. <i>Biochemistry</i> , <b>1998</b> , 37, 14167-74	3.2	18
36	7-Hydroxy-2-substituted-4-H-1-benzopyran-4-one derivatives as aldose reductase inhibitors: a SAR study. <i>European Journal of Medicinal Chemistry</i> , <b>2001</b> , 36, 697-703	6.8	18
35	Methoxylated 2-Hydroxychalcones as antiparasitic hit compounds. <i>European Journal of Medicinal Chemistry</i> , <b>2017</b> , 126, 1129-1135	6.8	17
34	Exploiting the 2-Amino-1,3,4-thiadiazole Scaffold To Inhibit Pteridine Reductase in Support of Early-Stage Drug Discovery. <i>ACS Omega</i> , <b>2017</b> , 2, 5666-5683	3.9	17
33	Synthesis and aldose reductase inhibitory activity of a new series of benz[h]cinnolinone derivatives. <i>Il Farmaco</i> , <b>2000</b> , 55, 544-52		17

32	Molecular dynamics simulations of the structure of aldose reductase complexed with the inhibitor tolrestat. <i>Bioorganic and Medicinal Chemistry Letters</i> , <b>1998</b> , 8, 641-6	2.9	16
31	Theoretical and experimental study of flavones as inhibitors of xanthine oxidase. <i>European Journal of Medicinal Chemistry</i> , <b>1995</b> , 30, 141-146	6.8	16
30	Inhibitors for proteins endowed with catalytic and non-catalytic activity which recognize pTyr. <i>Current Medicinal Chemistry</i> , <b>2004</b> , 11, 2725-47	4.3	15
29	Synthesis of novel benzoic acid derivatives with benzothiazolyl subunit and evaluation as aldose reductase inhibitors. <i>Archiv Der Pharmazie</i> , <b>2005</b> , 338, 411-8	4.3	15
28	An Overview on the Potential Antimycobacterial Agents Targeting Serine/Threonine Protein Kinases from Mycobacterium tuberculosis. <i>Current Topics in Medicinal Chemistry</i> , <b>2019</b> , 19, 646-661	3	15
27	New insight into structure-activity of furan-based salicylate synthase (MbtI) inhibitors as potential antitubercular agents. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , <b>2019</b> , 34, 823-828	5.6	14
26	The Impact of Lipid Corona on Rifampicin Intramacrophagic Transport Using Inhaled Solid Lipid Nanoparticles Surface-Decorated with a Mannosylated Surfactant. <i>Pharmaceutics</i> , <b>2019</b> , 11,	6.4	13
25	Drug delivery to the CNS and polymeric nanoparticulate carriers. <i>Future Medicinal Chemistry</i> , <b>2010</b> , 2, 1681-701	4.1	13
24	Ghrelin receptor modulators and their therapeutic potential. <i>Future Medicinal Chemistry</i> , <b>2009</b> , 1, 157-774.1	4.1	12
23	Synthesis and aldose reductase inhibitory activities of novel thienocinnolinone derivatives. <i>European Journal of Pharmaceutical Sciences</i> , <b>2004</b> , 21, 545-52	5.1	12
22	Enhancement of Benzothiazoles as Pteridine Reductase-1 Inhibitors for the Treatment of Trypanosomatidic Infections. <i>Journal of Medicinal Chemistry</i> , <b>2019</b> , 62, 3989-4012	8.3	11
21	Teaching an Undergraduate Organic Chemistry Laboratory Course with a Tailored Problem-Based Learning Approach. <i>Journal of Chemical Education</i> , <b>2019</b> , 96, 888-894	2.4	11
20	Free energy perturbation studies on binding of the inhibitor 5,6-dihydrobenzo[h]cinnolin-3(2H)one-2-acetic acid and its methoxylated analogs to aldose reductase. <i>Tetrahedron</i> , <b>1998</b> , 54, 9415-9428	2.4	11
19	Anti-inflammatory activity of newly synthesized 2,6-bis-(1,1-dimethylethyl)phenol derivatives. <i>Pharmacological Research</i> , <b>1993</b> , 27, 349-58	10.2	11
18	Inhibitory activity of flavonols towards the xanthine oxidase enzyme. <i>International Journal of Pharmaceutics</i> , <b>1992</b> , 86, 17-23	6.5	11
17	Design, synthesis and biological evaluation of non-covalent AmpC $\beta$ lactamases inhibitors. <i>Medicinal Chemistry Research</i> , <b>2017</b> , 26, 975-986	2.2	9
16	Ghrelin receptor modulators: a patent review (2011 - 2014). <i>Expert Opinion on Therapeutic Patents</i> , <b>2014</b> , 24, 1007-19	6.8	8
15	On the prodrug potential of novel aldose reductase inhibitors with diphenylmethylenaminoxyacetic acid structure. <i>European Journal of Pharmaceutical Sciences</i> , <b>2002</b> , 15, 11-20	5.1	8

14	Binding of 1-benzopyran-4-one derivatives to aldose reductase: a free energy perturbation study. <i>Bioorganic and Medicinal Chemistry</i> , <b>2002</b> , 10, 1427-36	3.4	8
13	A series of diarylsubstituted oximes as potential substrate for new aldose reductase inhibitors. <i>Journal of Heterocyclic Chemistry</i> , <b>2000</b> , 37, 1089-1096	1.9	7
12	Challenges in the design of clinically useful brain-targeted drug nanocarriers. <i>Current Medicinal Chemistry</i> , <b>2014</b> , 21, 4227-46	4.3	7
11	Folate: Relevance of Chemical and Microbial Production <b>2016</b> , 103-128		6
10	2-Deoxyuridine 5-phosphate substrate displacement in thymidylate synthase through 6-hydroxy-2-naphtho[1,8-bc]furan-2-one derivatives. <i>Journal of Medicinal Chemistry</i> , <b>2013</b> , 56, 9356-60	8.3	6
9	Quantitative measurement of proton dissociation and tautomeric constants of apigeninidin. <i>Journal of the Chemical Society Perkin Transactions II</i> , <b>1995</b> , 227		6
8	Growth hormone secretagogue receptor antagonists. <i>Expert Opinion on Therapeutic Patents</i> , <b>2012</b> , 22, 697-700	6.8	5
7	Synthesis and aldose reductase inhibitory activity of benzoyl-amino acid derivatives. <i>Il Farmaco</i> , <b>1998</b> , 53, 439-42		5
6	New perspectives on the development of antiobesity drugs. <i>Future Medicinal Chemistry</i> , <b>2015</b> , 7, 315-36	4.1	4
5	Heteroarylalkanoic acids with possible antiinflammatory activities, III. <i>Archiv Der Pharmazie</i> , <b>1985</b> , 318, 903-11	4.3	3
4	Methods for synthesis and uses of inhibitors of ghrelin O-acyltransferase inhibitors as potential therapeutic agents for obesity and diabetes. <i>Expert Opinion on Therapeutic Patents</i> , <b>2010</b> , 20, 1603-7	6.8	2
3	Novel triazole derivatives with improved receptor activity and bioavailability properties as ghrelin antagonists of growth hormone secretagogue receptors (WO2012035124): a patent evaluation. <i>Expert Opinion on Therapeutic Patents</i> , <b>2012</b> , 22, 1099-104	6.8	1
2	Solvent effects on the tautomerism of apigeninidin. <i>Tetrahedron Letters</i> , <b>1994</b> , 35, 9751-9754	2	1
1	Determination of drug-macromolecule binding parameters by numerical analysis. <i>Analytica Chimica Acta</i> , <b>1991</b> , 244, 145-149	6.6	